Join us in Philadelphia from Sept. 25-27th for our "Together We Will" Weekend: - Register today!

A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF inhibitor safety and preliminary antitumor activity in patients with desmoid tumors

November 18, 2025 by

Stay Up to Date as We Uncover More About Desmoid Tumors